Interestingly, we identified significant upregulation of ASXL1 expression in AML-ASXL1 samples compared to tissue-matched controls (log2FC = 0.46, padj= 1.11E-02) but no significant dysregulation of ASXL1 expression in BOS (Fig. 2H). This evidence concerns the gene ASXL1 and acute myeloid leukemia.